Arno Therapeutics, Inc: 10-Q filed 2015-11-16
What Arno Therapeutics, Inc reported in its quarterly report filed 2015-11-16 (fiscal Q3 2015): 27 published measures, 80 facts as tagged in accession 0001144204-15-065803.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2015-11-16
- Fiscal period
- fiscal Q3 2015
- Accession
- 0001144204-15-065803 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Arno Therapeutics, Inc filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 409,805 | USD | |
| At 2014-12-31 | 8,247,667 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 5,654,380 | USD | |
| At 2014-12-31 | 8,836,558 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | -5,244,575 | USD | |
| At 2014-12-31 | -588,891 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 123,272 | USD | |
| At 2014-12-31 | 7,948,436 | USD | |
| At 2014-09-30 | 11,576,575 | USD | |
| At 2013-12-31 | 26,774,203 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | -679,307 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -7,512,973 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 159,436 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 3,207,628 | USD | 273 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-09-30 | 0 | USD | 273 |
| 2014-01-01 to 2014-09-30 | 20,097 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | -89,299,963 | USD | |
| At 2014-12-31 | -81,786,990 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 20,408,616 | shares | 92 |
| 2015-01-01 to 2015-09-30 | 20,408,616 | shares | 273 |
| 2014-07-01 to 2014-09-30 | 20,376,573 | shares | 92 |
| 2014-01-01 to 2014-09-30 | 20,372,435 | shares | 273 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 20,408,616 | shares | 92 |
| 2015-01-01 to 2015-09-30 | 20,408,616 | shares | 273 |
| 2014-07-01 to 2014-09-30 | 24,801,853 | shares | 92 |
| 2014-01-01 to 2014-09-30 | 24,804,617 | shares | 273 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | -0.03 | USD/shares | 92 |
| 2015-01-01 to 2015-09-30 | -0.37 | USD/shares | 273 |
| 2014-07-01 to 2014-09-30 | 0.01 | USD/shares | 92 |
| 2014-01-01 to 2014-09-30 | 0.16 | USD/shares | 273 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | -0.03 | USD/shares | 92 |
| 2015-01-01 to 2015-09-30 | -0.37 | USD/shares | 273 |
| 2014-07-01 to 2014-09-30 | 0.01 | USD/shares | 92 |
| 2014-01-01 to 2014-09-30 | 0.13 | USD/shares | 273 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 24,908 | USD | |
| At 2014-12-31 | 30,730 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-09-30 | 2,857,289 | USD | 273 |
| 2014-01-01 to 2014-09-30 | 3,502,079 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | -2,874,789 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -10,716,273 | USD | 273 |
| 2014-07-01 to 2014-09-30 | -5,675,498 | USD | 92 |
| 2014-01-01 to 2014-09-30 | -17,602,769 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 374,442 | USD | |
| At 2014-12-31 | 8,206,482 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 349 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 1,139 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 0 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 0 | USD | 273 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 2,163,856 | USD | |
| At 2014-12-31 | 2,157,111 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 1,175,294 | USD | |
| At 2014-12-31 | 742,448 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 2,874,789 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 10,716,273 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 5,675,498 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 17,602,769 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 1,792,758 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 6,915,408 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 3,756,428 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 12,274,542 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 20,408,616 | shares | |
| At 2014-12-31 | 20,408,616 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 84,049,919 | USD | |
| At 2014-12-31 | 81,192,630 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 251,170 | USD | |
| At 2014-12-31 | 258,046 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 1,082,031 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 3,800,865 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 1,919,070 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 5,328,227 | USD | 273 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 2,195,301 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 3,196,814 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 5,824,847 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 20,775,450 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 2,195,482 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 3,203,300 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 5,834,934 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 20,810,397 | USD | 273 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-09-30 | 432,846 | USD | 273 |
| 2014-01-01 to 2014-09-30 | -1,736,017 | USD | 273 |
Inspect the source
- Entity
- Arno Therapeutics, Inc / CIK 0001195116
- Captured
- SEC response SHA-256
daf59b1b66be981617a28a70398e42d86562bef04d5c645d4ccff16477481049
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001195116.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))